Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rucaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 9/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | POLA1 | P09884 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rucaparib SCHEMBL29351768 | 1.00 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5746065 | 0.99 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29392034 | 0.99 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5747917 | 0.95 | PARP1 (0.90) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29379028 | 0.95 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL844872 | 0.95 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL6701932 | 0.95 | PARP1 (0.90) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL30413070 | 0.93 | PARP1 (0.87) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL6702365 | 0.92 | PARP1 (0.84) | PARP1PARP2DYRK3TNKSPGR | |
| SCHEMBL25150522 | 0.90 | PARP1 (0.81) | PARP1PARP2DYRK3TNKSPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3182975-B1 | HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | PHARMA& SCHWEIZ GMBH (CH) | 2025-10-01 | — | — | EP | claimed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | claimed |
| EP-4166558-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | claimed |
| US-11352362-B2 | Polymorph of rucaparib camsylate | SHANGHAI BEGREAT PHARMATECH (CN) | 2022-06-07 | — | — | US | claimed |
| US-20200291036-A1 | POLYMORPH OF RUCAPARIB CAMSYLATE AND PREPARATION METHOD THEREOF AND USE OF SAME | SHANGHAI BEGREAT PHARMATECH (CN) | 2020-09-17 | — | — | US | claimed |
| US-10709724-B2 | Methods of treating mitochondrial dysfunction | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2020-07-14 | — | — | US | claimed |
| US-20190247371-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO[6,7-B]INDOLE DERIVATIVES | ACADEMIA SINICA (TW) | 2019-08-15 | — | — | US | claimed |
| EP-3150610-B1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3515437-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO (6,7-B) INDOLE DERIVATIVES | Academia Sinica (TW) | 2019-07-31 | — | — | EP | claimed |
| US-10278974-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | PFIZER INC. (US) | 2019-05-07 | — | — | US | claimed |
| US-7268126-B2 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-ce]indol-6-one | AGOURON PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | claimed |
| EP-1799685-A2 | POLYMORPHIC AND AMORPHOUS FORMS OF THE PHOSPHATE SALT OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | Pfizer, Inc. (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1794163-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | Pfizer, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060100198-A1 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-ce]indol-6-one | AGOURON PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2006033003-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2006033007-A2 | POLYMORPHIC AND AMORPHOUS FORMS OF THE PHOSPHATE SALT OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | claimed |
| EP-1611137-A1 | SALTS OF TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | PFIZER INC. (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040248879-A1 | Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | claimed |
| WO-2004087713-A1 | SALTS OF TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | PFIZER INC. (US) | 2004-10-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248879-A1 | Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 7/4885 |
| US-20060100198-A1 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-ce]indol-6-one | IMPA1, INPP5B, ITPA | PARP1 21/4885PARP2 411/4885PARP3 775/4885 |
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885PARP3 10/4885 |
| US-10278974-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | BRCA1, IMPA1, PARP1 | PARP1 3/4885PARP2 57/4885PARP3 148/4885 |
| US-20200291036-A1 | POLYMORPH OF RUCAPARIB CAMSYLATE AND PREPARATION METHOD THEREOF AND USE OF SAME | TYMP, CPSF7, CPSF6 | PARP1 40/4885PARP2 299/4885PARP3 401/4885 |
| US-20190247371-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO[6,7-B]INDOLE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RB1, INMT | PARP1 730/4885PARP2 664/4885PARP3 711/4885 |
| US-11352362-B2 | Polymorph of rucaparib camsylate | TPMT, CPSF7, TYMP | PARP1 20/4885PARP2 270/4885PARP3 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.